Synakis Announces Close of Oversubscribed Pre-Seed Round

TORONTO, May 21, 2026 /PRNewswire/ - Synakis Corp., a Toronto-based biotechnology company developing ocular therapies for retinal disease and glaucoma, announced today the close of an oversubscribed CAD $2.6 million pre-seed financing round to advance SNK-125, its vitreous replacement...